Gschwantler M, Dragosics B, Schütze K, Wurzer H, Hirschl A M, Pasching E, Wimmer M, Klimpfinger M, Oberhuber G, Brandstätter G, Hentschel E, Weiss W
The 4th Department of Internal Medicine, KA Rudolfstiftung, Vienna, Austria.
Aliment Pharmacol Ther. 1999 Aug;13(8):1063-9. doi: 10.1046/j.1365-2036.1999.00563.x.
One-week low-dose triple therapy is currently considered the gold standard regimen for treatment of Helicobacter pylori infection. However, the mechanisms involved in the synergy between antibiotics and proton pump inhibitors are controversial.
To test the hypothesis that acid suppression represents the crucial mechanism by which the antibacterial activity of antibiotics can be enhanced, and to assess the impact of primary resistance on treatment outcome.
One hundred and twenty patients with H. pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 60) or omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 60). Gastroscopy was performed at baseline and 5 weeks after completion of treatment. H. pylori status was assessed by biopsy urease test, histology and culture.
In the intention-to-treat analysis, eradication of H. pylori was achieved in 47 of 60 patients (78%; 95% CI: 66-88%) in the FCM group, compared to 44 of 60 patients (73%; 95% CI: 60-84%) in the OCM group (N.S.). Using per protocol analysis, eradication therapy was successful in 47 of 52 patients (90%; 95% CI: 79-97%) treated with FCM and 44 of 57 patients (77%; 95% CI: 64-87%) treated with OCM (N.S.). Primary metronidazole resistance was present in 27% and primary clarithromycin resistance in 8% of strains. Overall per protocol eradication rates in strains susceptible to both antibiotics and strains with isolated metronidazole resistance were 93% and 84%, respectively. No patient with clarithromycin resistance responded to treatment.
High-dose famotidine and omeprazole, combined with clarithromycin and metronidazole, are equally effective for eradication of H. pylori. In 1-week low-dose triple therapy, metronidazole resistance has no major impact on eradication rates whereas clarithromycin resistance is associated with a poor treatment outcome.
目前,一周低剂量三联疗法被认为是治疗幽门螺杆菌感染的金标准方案。然而,抗生素与质子泵抑制剂协同作用的机制仍存在争议。
验证酸抑制是增强抗生素抗菌活性的关键机制这一假说,并评估原发耐药对治疗结果的影响。
120例幽门螺杆菌感染且患有十二指肠溃疡、胃溃疡或非溃疡性消化不良的患者被随机分为两组,每组60例。一组接受法莫替丁80mg每日两次、克拉霉素250mg每日两次和甲硝唑500mg每日两次的1周疗程治疗(FCM组);另一组接受奥美拉唑20mg每日一次、克拉霉素250mg每日两次和甲硝唑500mg每日两次的1周疗程治疗(OCM组)。在基线期和治疗结束后5周进行胃镜检查。通过活检尿素酶试验、组织学检查和培养评估幽门螺杆菌感染状态。
在意向性分析中,FCM组60例患者中有47例(78%;95%可信区间:66 - 88%)实现了幽门螺杆菌根除,而OCM组60例患者中有44例(73%;95%可信区间:60 - 84%)实现了根除(无统计学差异)。按照符合方案分析,接受FCM治疗的52例患者中有47例(90%;95%可信区间:79 - 97%)根除治疗成功,接受OCM治疗的57例患者中有44例(77%;95%可信区间:64 - 87%)根除治疗成功(无统计学差异)。27%的菌株存在甲硝唑原发耐药,8%的菌株存在克拉霉素原发耐药。对两种抗生素均敏感的菌株和仅对甲硝唑耐药的菌株的总体符合方案根除率分别为93%和84%。没有对克拉霉素耐药的患者对治疗有反应。
高剂量法莫替丁和奥美拉唑联合克拉霉素及甲硝唑在根除幽门螺杆菌方面同样有效。在1周低剂量三联疗法中,甲硝唑耐药对根除率没有重大影响,而克拉霉素耐药与治疗效果不佳相关。